1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GABAPENTIN MARKET, BY TYPE
5.1. Introduction
5.2. Generic
5.3. Branded
6. GABAPENTIN MARKET, BY APPLICATION
6.1. Introduction
6.2. Epilepsy
6.3. Neuropathic Pain
6.4. Restless Legs Syndrome
6.5. Others
7. GABAPENTIN MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Others
8. GABAPENTIN MARKET, BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. The Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Israel
8.5.4. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. Pfizer
10.2. Fierce Pharma
10.3. Mayo Clinic
10.4. Ralington Pharma
10.5. Teva Pharmaceuticals
10.6. Gralise
10.7. Glenmark Pharmaceuticals
10.8. Stensa Lifesciences
10.9. Rosemont Pharmaceuticals
10.10. Lupin